38个高负担低收入和中等收入国家的艾滋病毒支出模式、决定因素及其对护理和治疗的影响。
Pattern, Determinants, and Impact of HIV Spending on Care and Treatment in 38 High-Burden Low- and Middle-Income Countries.
作者信息
Granich Reuben, Gupta Somya, Montaner Julio, Williams Brian, Zuniga José M
机构信息
International Association of Providers of AIDS Care, Washington DC, USA
International Association of Providers of AIDS Care, Washington DC, USA.
出版信息
J Int Assoc Provid AIDS Care. 2016 Mar-Apr;15(2):91-100. doi: 10.1177/2325957415623261. Epub 2015 Dec 28.
UNLABELLED
: Achieving the 90-90-90 targets by 2020 requires increased focus, resources, and efficiency to provide earlier access to antiretroviral therapy (ART).
METHODS
We used 2009 to 2013 National AIDS Spending Assessment data to assess HIV care and treatment spending in 38 high-burden, low- and middle-income countries (LMICs).
RESULTS
In 2013, 23 of the 38 high-burden countries spent less than 50% of total HIV spending on care and treatment. HIV spending on ART per people living with HIV (PLHIV; adjusted) averaged US$299 (US$32-US$2463). During 2009 to 2013, a 10% increase in average spending on care and treatment per PLHIV was associated with an increase in ART coverage of 2.4% and a decrease in estimated AIDS-related death rate of 2.4 per 1000 PLHIV.
DISCUSSION
HIV spending in high-burden LMICs does not consistently reflect the new science around the preventative and clinical benefits of earlier HIV diagnosis and ART initiation.
未标注
到2020年实现90-90-90目标需要加大关注力度、投入资源并提高效率，以便更早地提供抗逆转录病毒疗法（ART）。
方法
我们使用2009年至2013年国家艾滋病支出评估数据，评估了38个高负担低收入和中等收入国家（LMICs）的艾滋病毒护理和治疗支出。
结果
2013年，38个高负担国家中有23个国家用于护理和治疗的艾滋病毒支出不到总支出的50%。每位艾滋病毒感染者（PLHIV；经调整）的抗逆转录病毒疗法支出平均为299美元（32美元至2463美元）。在2009年至2013年期间，每位艾滋病毒感染者护理和治疗平均支出增加10%，与抗逆转录病毒疗法覆盖率提高2.4%以及每1000名艾滋病毒感染者估计艾滋病相关死亡率降低2.4%相关。
讨论
高负担低收入和中等收入国家的艾滋病毒支出并不能始终反映围绕早期艾滋病毒诊断和开始抗逆转录病毒疗法的预防和临床益处的新科学。
Zotero 插件